2022), we show that all four fucosylation inhibitors can inhibit fucosylation in both androgen receptor (AR) negative PC3 and AR positive CWR22RV1 prostate cancer cells (Fig. 2A–D), although with different effectiveness, especially for Fucotrim I. See Table 1 for the IC50 and IC70-values (the concentration where a 50% or 70% decrease in lectin binding compared to control was observed). The gene discussed is AR; the disease is prostate carcinoma.